Su, Peiran
Liu, Yin
Chen, Tianyi
Xue, Yibo
Zeng, Yong https://orcid.org/0000-0001-5719-1272
Zhu, Guanghui https://orcid.org/0000-0003-1495-4238
Chen, Sujun https://orcid.org/0000-0002-1941-3951
Teng, Mona
Ci, Xinpei
Guo, Mengdi
He, Michael Y. https://orcid.org/0000-0002-2235-2758
Hao, Jun https://orcid.org/0000-0002-8989-8771
Chu, Vivian
Xu, Wenxi
Wang, Shiyan
Mehdipour, Parinaz https://orcid.org/0000-0002-4476-9925
Xu, Xin https://orcid.org/0000-0003-4670-1243
Marhon, Sajid A. https://orcid.org/0000-0002-1046-9852
Soares, Fraser https://orcid.org/0000-0002-3977-7939
Pham, Nhu-An https://orcid.org/0000-0003-3063-0292
Wu, Bell Xi
Her, Peter Hyunwuk
Feng, Shengrui
Alshamlan, Najd
Khalil, Maryam
Krishnan, Rehna
Yu, Fangyou
Chen, Chang https://orcid.org/0000-0003-2841-1250
Burrows, Francis
Hakem, Razqallah
Lupien, Mathieu
Harding, Shane
Lok, Benjamin H.
O’Brien, Catherine
Berlin, Alejandro https://orcid.org/0000-0002-1880-6905
De Carvalho, Daniel D.
Brooks, David G.
Schramek, Daniel https://orcid.org/0000-0001-9977-2104
Tsao, Ming-Sound https://orcid.org/0000-0002-9160-5405
He, Housheng Hansen https://orcid.org/0000-0003-2898-3363
Funding for this research was provided by:
Princess Margaret Cancer Foundation (886012001223)
Gouvernement du Canada | Canadian Institutes of Health Research (142246, 152863,152864,159567,438793, FDN-148395)
Terry Fox Research Institute (1090, 1124)
National Natural Science Foundation of China (31801111)
Article History
Received: 10 November 2023
Accepted: 18 July 2024
First Online: 3 September 2024
Competing interests
: F.B. is Vice President of Translational Research of Kura Oncology, Inc. The other authors declare no competing interests.